The neurological disorder drug developer has floated in an initial public offering that gave pharmaceutical companies Sanofi and Takeda exits.

The implantable medical device developer has achieved the first close of a series C round featuring Legend Capital that has a target size of $30m.

British Columbia University has signed a licensing agreement with Commonsense for a treatment of asthma and other allergic conditions.

Boehringer Ingelheim Venture Fund has co-led a $21.8m round for ImCheck Therapeutics, established with the support of Satt Sud-Est.

Novartis Venture Fund co-led the gene therapy developer's series A round, which also included funding from Roche Venture Fund.

Hoya Group's corporate venturing unit has led a series A round for fluid-optic intraocular lens developer LensGen which could be increased to $26m.

The insurance firm, which has had a dedicated venture capital unit since 2012, will invest in healthcare and financial technology developers through the Ping An Global Voyager Fund.

Boehringer Ingelheim Venture Fund has co-led a $21.8m round for ImCheck Therapeutics, which announced its new CEO in conjunction with the funding.